Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India’s Dr. Reddy’s Seen Hit Most From Try To Ban Favored Generics

This article was originally published in PharmAsia News

Executive Summary

A piece of U.S. legislation could have a large negative impact on Indian generics maker Dr. Reddy's Laboratories. U.S. Congress is considering a bill that would have the effect of banning the transfer of authorized generics rights from multinational pharmaceutical companies to a third party. In particular, the measure would have a negative impact on Dr. Reddy's approved generic of GlaxoSmithKline's Imitrex (sumatriptan) for migraines, which the firm launched last November. Among the beneficiaries could be generics makers such as Cipla, Sun Pharma and others not chosen by GSK as the generics-maker of choice. (Click here for more
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC071079

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel